Searching for trends in recent FTC consent orders and related motions
The FTC’s June 9, 2014, consent order for i-Health Inc. and Martek Biosciences bans the companies from making any product claims of improving memory or preventing cognitive decline unless the company has “competent and reliable scientific evidence” comprising “human clinical testing that is sufficient in quality and quantity, based on standards generally accepted by experts in cognitive science, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true. Such testing shall be randomized, double-blind, and placebo-controlled; and be conducted by researchers qualified by training and experience to conduct such testing.” However, the FTC does not specify how many trials are needed.
One Commissioner described the MIDAS study Memory Improvement with Docosahexaenoic Acid Study (MIDAS), which the companies used as evidence, as well conducted, but said that “its results were inconsistent and insufficiently robust to support claims about noticeable improvements in everyday memory...”
But not all of the Commission agreed. Commissioner Maureen K. Ohlhausen dissented with the rest. She wrote that the FTC’s complaint against BrainStrong “imposes an unduly high standard of substantiation on a safe product,” and that the MIDAS study did adequately substantiate the claims. Also, she wrote this:
This unduly high standard not only risks denying consumers useful information in the present but may also, in the long term, diminish incentives to conduct research on the health effects of foods and supplements and reduce the incentives of manufacturers to introduce such products. The majority’s approach may ultimately undermine an efficient and reliable competitive market process and make consumers worse off.
FTC Requirement: Human studies (but doesn’t specify number of studies)
<<Previous Next>>
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/adventtr
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”